- Cell-Based
- Non-Cell-Based
Cartilage Degeneration Market size is valued at USD 13,926.2 million in 2022 and is poised to grow at a CAGR of 5.9% from 2023 to 2029. The global market provides a detailed overview and which can be segmented by treatment modality, application, type of treatment, site of action, end user, and region. By treatment modality, the cartilage degeneration market has been segmented into cell-based, and non-cell-based. By treatment modality, the cell-based segment held the largest revenue share of the cartilage degeneration market in past years and is expected to have the fastest growth rate over the forecasted period due rise in cartilage degeneration among various aged people which leads to enhances demand for cell-based cartilage treatment. By application, the Cartilage degeneration market has been segmented into hyaline cartilage and fibrocartilage. By application, the fibrocartilage segment held the largest revenue share of the gastric cancer therapy market in past years and is expected to have the fastest growth rate over the forecasted period due to a high prescription rate. By type of treatment, the Cartilage degeneration market has been segmented into palliative and intrinsic repair stimuli. By the site of action, the cartilage degeneration market has been segmented into knee cartilage repair. The knee segment accounted for the highest share of the market. The growth of this segment is attributed to the increasing prevalence of knee injuries. For instance, according to a study published in an online newspaper, which is based on NCBI data, an estimated 1 in 4 adults suffer from chronic knee pain. Moreover, the prevalence of knee pain has witnessed a massive growth of around 40.0% during the past 4 decades. Furthermore, increasing awareness of the benefits provided by cartilage repair is also anticipated to drive the growth of the knee segment. Based on the end user, the segment has been segregated into hospitals, diagnostic centers, orthopedic hospitals, and ambulatory surgical centers. The ambulatory surgical clinic segment held the largest share of the market in 2019. Also, the segment is expected to register the highest CAGR in the market during the forecast period.
Cartilage Degeneration Market Key Developments:
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
Obesity has a substantial effect on the musculoskeletal system, resulting in the degeneration of bones, cartilage, and ligaments. Furthermore, the condition, along with other prominent factors, is strongly related to the increased risk of rapid cartilage loss. The increasing prevalence of obesity is anticipated to accelerate the incidence of cartilage degeneration, which will further drive market growth.
The major factors driving the market growth are increasing number of sports injuries, and the rising prevalence of obesity.
The global Cartilage degeneration market size is valued at USD 13,926.2 million in 2021 and is expected to grow at a CAGR of 5.9% during the forecast period 2022 to 2028.
North America dominated the global cartilage degeneration market and held a significant market share, and would expand to dominate the global market by making huge investments in healthcare sectors.
Product launches and acquisitions are the two key strategies opted by the leading companies in the market.
1. Executive Summary |
2. Global Cartilage Degeneration Market Introduction |
2.1.Global Cartilage Degeneration Market - Taxonomy |
2.2.Global Cartilage Degeneration Market - Definitions |
2.2.1.Treatment Modality |
2.2.2.Application |
2.2.3.End User |
2.2.4.End User |
2.2.5.Region |
3. Global Cartilage Degeneration Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Cartilage Degeneration Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Cartilage Degeneration Market By Treatment Modality, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Cell-Based |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Non-Cell-Based |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6. Global Cartilage Degeneration Market By Application, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Fibrocartilage |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Hyaline Cartilage |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Cartilage Degeneration Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Diagnostic centres |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Orthopaedic Clinics |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Ambulatory surgical centres |
7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
8. Global Cartilage Degeneration Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. Pharma Companies |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Biotech Companies |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Academic Research Labs |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Private Biobanks |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
9. Global Cartilage Degeneration Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10. North America Cartilage Degeneration Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Treatment Modality Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Cell-Based |
10.1.2.Non-Cell-Based |
10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Diagnostic centres |
10.3.3.Orthopaedic Clinics |
10.3.4.Ambulatory surgical centres |
10.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Pharma Companies |
10.4.2.Biotech Companies |
10.4.3.Academic Research Labs |
10.4.4.Private Biobanks |
10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11. Europe Cartilage Degeneration Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Treatment Modality Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Cell-Based |
11.1.2.Non-Cell-Based |
11.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Fibrocartilage |
11.2.2.Hyaline Cartilage |
11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Diagnostic centres |
11.3.3.Orthopaedic Clinics |
11.3.4.Ambulatory surgical centres |
11.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Pharma Companies |
11.4.2.Biotech Companies |
11.4.3.Academic Research Labs |
11.4.4.Private Biobanks |
11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
11.5.6.Rest of EU |
12. Asia Pacific (APAC) Cartilage Degeneration Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Treatment Modality Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Cell-Based |
12.1.2.Non-Cell-Based |
12.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Fibrocartilage |
12.2.2.Hyaline Cartilage |
12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Diagnostic centres |
12.3.3.Orthopaedic Clinics |
12.3.4.Ambulatory surgical centres |
12.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Pharma Companies |
12.4.2.Biotech Companies |
12.4.3.Academic Research Labs |
12.4.4.Private Biobanks |
12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13. Middle East and Africa (MEA) Cartilage Degeneration Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Treatment Modality Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Cell-Based |
13.1.2.Non-Cell-Based |
13.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Fibrocartilage |
13.2.2.Hyaline Cartilage |
13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Diagnostic centres |
13.3.3.Orthopaedic Clinics |
13.3.4.Ambulatory surgical centres |
13.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Pharma Companies |
13.4.2.Biotech Companies |
13.4.3.Academic Research Labs |
13.4.4.Private Biobanks |
13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14. Latin America Cartilage Degeneration Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
14.1. Treatment Modality Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Cell-Based |
14.1.2.Non-Cell-Based |
14.2. Application Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Fibrocartilage |
14.2.2.Hyaline Cartilage |
14.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Hospitals |
14.3.2.Diagnostic centres |
14.3.3.Orthopaedic Clinics |
14.3.4.Ambulatory surgical centres |
14.4. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Pharma Companies |
14.4.2.Biotech Companies |
14.4.3.Academic Research Labs |
14.4.4.Private Biobanks |
14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Zimmer Biomet Holdings, Inc. (U.S.) |
15.2.2.Vericel Corporation (U.S.) |
15.2.3.Smith & Nephew plc (U.K.) |
15.2.4.Osiris Therapeutics, Inc. (U.S.) |
15.2.5.Arthrex Inc. (U.S.). |
16. Research Methodology |
17. Appendix and Abbreviations |